In this compelling OIS podcast episode, host Dr. Rob Rothman engages in an insightful conversation with Dr. Malvina Eydelman, the Director of the FDA's Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices. Delve into Malvina's unique career journey and discover how her diverse background in engineering and ophthalmology has influe…

In the latest episode of the OIS podcast, host Dr. Rob Rothman delves into the transformative power of empathy with multi-Emmy award-winning actress and writer, Ellen Gould. Together, they explore the intersection of healthcare and storytelling, shedding light on the importance of patient-centered care and authentic narrative representation. Episod…

In this episode, Dr. Jai Parekh shares his journey from ophthalmology to business leadership in healthcare. Raised in New Jersey, he initially pursued cardiology before discovering his passion for ophthalmology. Specializing in cornea and refractive surgery, he transitioned into the commercial side of the field, leveraging his clinical expertise an…

Don't miss the latest episode of the OIS Retina Podcast, where we sit down with optometrist and ophthalmology researcher Brian Levy for an illuminating discussion on the future of eye care. In this episode, Brian takes us on a journey through his career, from his early days in vet school to his groundbreaking work at Presbyterian Medical Center, Ae…

Tune in to the latest episode of the Eye On Innovation podcast where Carey Powers dives into the dynamic world of biotech investor pitch decks with special guest Dr. Rob Rothman, Founding Partner of InFocus Capital Partners. Discover the top five mistakes to avoid when crafting your pitch deck and gain exclusive insights from Dr. Rothman's wealth o…

Join us this week on the OIS podcast as host Carey Powers sits down with Dr. Paul Karpecki to explore the latest advancements in presbyopia treatment strategies. Here's what you can expect from this insightful conversation: Insider Insights: Dr. Karpecki shares insider insights gleaned from his extensive clinical experience and research in the fiel…

In the latest episode of the OIS Podcast, host Dr. Robert Rothman engages in a captivating dialogue with Dr. Prasad Sunkara, CEO of Eyegenex. Key points discussed in the episode: Prasad's multifaceted background spanning agricultural sciences to pharmaceuticals. Eyegenex's pioneering work in gene and peptide therapies for ophthalmic conditions. The…

This panel discussion on startup commercial strategy explores key elements and insights from industry leaders, Paul Bresge, Aziz Mottiwala, Todd Pinkney, Cari Stone and Adam Szaronos, offering a comprehensive view of the journey from regulatory approval to commercialization. Beth Marsh, Lead of Sales and Marketing at Apellis, sets the stage by emph…

OIS Podcast host Carey Powers speaks with Dr. Adrienne Graves and Dr. Barbara Wirostko on 'Maximizing the Value of Your Board of Director' live from OIS XIII. Dr. Graves and Dr. Wirostko share valuable insights on: * Building effective boards * Significance of diversity * CEO and board member communications * Navigating decision-making * Board dyna…

By OIS Podcast

In this episode of the OIS Podcast, host Dr. Firas Rahhal, along with expert panelists, Dr. Robert Bhisitkul, Dr. Alan Franklin and Dr. Paul Karpecki at OIS XIII, takes listeners on a deep dive into the transformative landscape of oral therapies in retina treatment, challenging the conventional approach dominated by eye injections. Tune in as they …

ViaLase, a clinical stage medical technology company located in Aliso Viejo, CA is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care. With a leadership team that has vast experience developing, designing, manufa…

Opthea, an Australian based biopharmaceutical company is dedicated to transforming retinal disease treatments and elevating patients' vision and quality of life. Join Firas Rahal, MD, in a captivating episode as he engages with Opthea's Founder and Chief Innovation Officer, Megan Baldwin, PhD. Explore the compelling journey from oncology to ophthal…

Harrow isn’t a household name (yet), but eye care professionals have trusted its products for over a decade. The Nashville-based company produces Dexycu, an intraocular steroid; Iopidine for intraocular pressure control; and most recently, five Novartis products that Harrow acquired in December 2022. Rob Rothman, MD, caught up with Harrow founder a…

Endogena Therapeutics has developed a novel approach to regenerative medicine that’s not only scientifically compelling, but practical. Endogena’s technology unlocks the body’s own stem cells for controlled tissue repair by small molecules. Its products use a dosing schedule that could move easily into the system already in place for intravitreal i…

“You can see and feel a buzz within the company right now,” said Andrew Stewart, President, Global Pharmaceuticals and International Consumer, at Bausch + Lomb. Bausch + Lomb’s current momentum stems not only from new leadership, but also from recent collaborations, partnerships, and acquisitions. Stewart and Yehia Hashad, MD, Executive Vice Presid…

OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D. Her guests include: Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics Michael Tsipursky, MD, CEO and Cofounder of Revive Biotech Michael S…

OIS Podcast host Carey Powers speaks with four CEOs from leading retina-focus companies to talk about all things innovation. Her guests include: • Kerrie Brady, BPharm, President and CEO of OcuTerra • Rich Small, CEO of NeuroTech Pharmaceuticals • Kester Nahen, PhD, CEO of Notal Vision • Brad Doerschuk, President and CEO of InFocus Clinical OcuTerr…

At-home OCT enables daily monitoring of patients with neovasular age-related macular degeneration (AMD) and other patients that need a lot of follow-ups. With host Carey Powers, Dr. Anat Loewenstein dives into at-home OCT innovation, application, and adoption. Dr. Loewenstein is Head of the Department of Ophthalmology and Vice Dean at Tel Aviv Medi…

Keith Valentine is the first and only visually impaired head of a national sight loss organization in the UK. As the President and CEO of Vision Foundation, London’s leading sight loss charity, Valentine guides an organization that provides services for blind and visually impaired people countrywide. He also has plans to increase the organization’s…

Two recent drug approvals changed the game for ocular surface disease: Xdemvy (lotilaner ophthalmic solution) 0.25 percent (Tarsus Pharmaceuticals) for Demodex blepharitis, and Miebo (perfluorohexyloctane ophthalmic solution) from Bausch + Lomb and Novaliq for evaporative dry eye disease. On today’s podcast, two ocular surface disease experts talk …

Yari Mitchell spent nearly 13 years with AcuFocus, an ophthalmic device company, before overseeing its acquisition by Bausch + Lomb. As head of Y Factor Consulting, she now helps innovators move their product from the lab to a funded company. Greg Kunst, President and CEO of Aurion Biotech, a cell therapy company, led the start-up to a $120 million…

Wesley Jackson, PhD, spent years conducting post-doctoral research and writing grants, all the while setting the wheels in motion to launch Valitor. Valitor is developing VLTR-557 a long-lasting anti-VEGF. The technology platform, a multivalent polymer (MVP), is integral to VLTR-557. With Firas Rahhal, MD, Dr. Jackson shares why he stuck with the s…

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, says the company looks for honest unmet needs when deciding what targets to explore. It also looks for opportunities to be the first or the best. The company may meet both objectives with TP-03, an antiparasitic agent developed to treat Demodex blepharitis, among other conditions. …

Daniela Ferrara, Principal Medical Director at Genentech, calls her extensive medical training in Brazil her “north star.” Yet, she was frustrated by the limitations of clinical practice. “Having patients go blind under my watch, I realized I would never defeat blindness through practice,” she said. She turned her attention to clinical research, wh…